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Non-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often undergo alloge-
neic hematopoietic cell transplantation (HCT). We analyzed Center for International Blood and Marrow
Transplant Research data on 1248 patients age 40 years receiving reduced-intensity conditioning (RIC) or
nonmyeloablative (NMA) conditioning HCT for aggressive (n ¼ 668) or indolent (n ¼ 580) NHL. Aggressive
lymphoma was more frequent in the oldest cohort 49% for age 40 to 54 versus 57% for age 55 to 64 versus 67%
for age 65; P ¼ .0008). Fewer patients aged 65 had previous autografting (26% versus 24% versus 9%; P ¼
.002). Rates of relapse, acute and chronic GVHD, and nonrelapse mortality (NRM) at 1 year post-HCT were
similar in the 3 age cohorts (22% [95% conﬁdence interval (CI), 19% to 26%] for age 40 to 54, 27% [95% CI, 23% to
31%] for age 55 to 64, and 34% [95% CI, 24% to 44%] for age 65. Progression-free survival (PFS) and overall
survival (OS) at 3 years was slightly lower in the older cohorts (OS: 54% [95% CI, 50% to 58%] for age 40 to 54;
40% [95% CI, 36% to 44%] for age 55 to 64, and 39% [95% CI, 28% to 50%] for age 65; P < .0001). Multivariate
analysis revealed no signiﬁcant effect of age on the incidence of acute or chronic GVHD or relapse. Age 55
years, Karnofsky Performance Status <80, and HLA mismatch adversely affected NRM, PFS, and OS. Disease
status at HCT, but not histological subtype, was associated with worse NRM, relapse, PFS, and OS. Even for
patients age 55 years, OS still approached 40% at 3 years, suggesting that HCT affects long-term remission
and remains underused in qualiﬁed older patients with NHL.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The use of allogeneic hematopoietic cell transplantation
(HCT) to treat non-Hodgkin lymphoma (NHL) is increasing
in patients with high-risk and relapsed/refractory disease
[1]. Considering that more than one-half of such NHL cases
are diagnosed in individuals age >65 years, this represents
a growing population of patients for whom allogeneic HCT
may provide long-term disease-free survival and improve
outcomes [2]. It has been postulated that conventional
myeloablative conditioning before HCT is not feasible for
the vast majority of older patients owing to limited physi-
ological resilience and accompanying comorbidities. Non-
myeloablative (NMA) conditioning and reduced-intensity
conditioning (RIC) strategies have made HCT available to
less-ﬁt individuals with relapsed or poor-risk hematologic
malignancies amenable to allogeneic HCT. Recent studies
have reported acceptable nonrelapse mortality (NRM) rates
of 10% to 20% and 2- to 3-year progression-free survival
rates of 25% to 75% depending on NHL subtype [3-7];
however, data speciﬁc to older patients with NHL remain
limited.
We recently examined the inﬂuence of age on outcomes
in older patients with acute myelogenous leukemia (AML) or
myelodysplastic syndrome (MDS) in ﬁrst complete remission
(CR) and found similar outcomes as seen in younger patients
when given an RIC HCT regimen [8]. In the present study, we
examined the same question in older patients undergoing
RIC or NMA allogeneic HCT for NHL of aggressive or indolent
histology, with the aim of deﬁning post-HCT outcomes in
older patients and evaluating patient, disease, and treatment
characteristics inﬂuencing these outcomes.
PATIENTS AND METHODS
Data for this analysis were submitted to the Center for International
Blood and Transplant Research (CIBMTR), a voluntary working group of
more than 450 transplant centers worldwide who contribute data on
consecutive allogeneic HCTs to a statistical center housed at the Medical
College of Wisconsin in Milwaukee and the National Marrow Donor Pro-
gram in Minneapolis. Patients are followed longitudinally with yearly
follow-up. Computerized checks for errors and onsite audits of participating
centers ensure data quality. Physician review of data and additional
requested information from reporting centers are included. Observational
studies conducted by the CIBMTR are performed with a waiver of informed
consent and in compliance with Health Insurance Portability and Account-
ability Act (HIPAA) regulations as determined by the Institutional Review
Board and the Privacy Ofﬁcer of the Medical College of Wisconsin.Patient Selection
The study group included patients age 40 years undergoing RIC or
NMA HCT between 2001 and 2007 for aggressive NHL (ie, diffuse large B cell
[n ¼ 202], mantle cell [n ¼ 279], immunoblastic/anaplastic B/T cell [n ¼ 52],
peripheral T cell [n ¼ 60], peripheral T cell lymphoma not otherwise spec-
iﬁed [n ¼ 25], Burkitt lymphoma [n ¼ 4], other [n ¼ 46]) and indolent NHL
(ie, small lymphocytic lymphoma [SLL]/chronic lymphocytic leukemia [CLL]
[n ¼ 156], follicular [n ¼ 387], marginal zone [n ¼ 13], and other [n ¼ 24]).
Patients were classiﬁed as being in ﬁrst (n ¼ 87) or second (n ¼ 231)
complete remission (CR), in ﬁrst (n ¼ 478) or second (n ¼ 304) partial
remission (PR), or with resistant disease (RD; n¼ 304) as known before HCT.
Grafts were from a related donor or an unrelated donor (URD); cord blood
grafts were not studied. Patients who underwent previous autologous HCT
were included.
A total of 1248 cases were identiﬁed, including 668 patients with
aggressive NHL and 580 patients with indolent NHL treated at 165 centers.
There were 1119 patients with B cell histology and 106 patients with T cell
histology; 3 patientswere not classiﬁable. Patients ranged in age from40 to 75
years and were divided into 3 age cohorts for analysis: 40 to 54 years (n ¼
614); 55 to 64 years (n¼ 552), and65 years (n¼ 82). Previously established
criteria for donorerecipient HLAmatchingwere used to deﬁnewell-matched,
partially matched, andmismatched categories [9]. Preparative regimenswere
classiﬁed as either RIC or NMA. RIC regimens included 500 cGy total body
irradiation as a single fraction or800 cGy if fractionated,9mg/kg busulfan
oral (or i.v. equivalent), <140 mg/m2 melphalan, <10 mg/kg thiotepa, and
BEAM (carmustine, etoposide, cytarabine, and melphalan) [10,11]. Other
regimens were classiﬁed as NMA when hematopoietic recovery without
transplantation within 28 days could be reasonably expected [12]. T cell
depletion accomplished via ex vivo or in vivo methods was included.Study Endpoints and Deﬁnitions
Primary outcomes were overall survival (OS) and progression-free sur-
vival (PFS), deﬁned as survival from allogeneic HCT without death and
without disease progression or relapse, respectively. NRM was deﬁned as
any death occurring in the ﬁrst 28 days post-transplantation or any death
after day þ28 without documented NHL progression or relapse. All data
were censored at the date of last reported follow-up. Secondary endpoints
included neutrophil recovery, deﬁned as the time to an absolute neutrophil
count of 500 cells/mL sustained for 3 consecutive days, and the cumulative
incidence of acute (grade II-IV) and chronic graft-versus-host disease
(GVHD) as deﬁned by consensus criteria [13,14].Statistical Analysis
Patient-, disease-, and transplantation-related variables were compared
in the 3 age cohorts using the chi-square test for categorical variables and
the Kruskal-Wallis test for continuous variables. Univariate probabilities of
PFS and OS were calculated using the Kaplan-Meier estimator, with variance
estimated using Greenwood’s formula. Probabilities of neutrophil recovery,
acute and chronic GVHD, NRM, and relapse were calculated using cumula-
tive incidence curves to accommodate competing risks. The 95% conﬁdence
intervals (CIs) for all probabilities and P values of pairwise comparisons were
derived from pointwise estimates and calculated using standard techniques.
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logistic regression. Cox proportional hazards regression models were used
for all other outcomes. The proportional hazards assumption was tested for
all variables. Variables were stratiﬁed in themodel when the proportionality
assumption did not hold [15]. Patient-, disease-, and transplantation-related
variables were considered in the model building procedure, with recipient
agedthe main focus of this studydincluded in all steps of model building.
Separate analyses of patients in CR1 versus those in CR2 and of patients in PR1
versus those in PR2 identiﬁed no signiﬁcant differences in major endpoints,
and thus these groupswere combined for subsequent analysis. Patient-related
variables consideredwere sex and Karnofsky Performance Status (KPS) of<80
versus 80. Disease-related variables included histology subtype (aggressive
versus indolent), disease status at time of HCT (CR1/2þ versus PR1/2þ versusTable 1
Characteristics of 1248 Patients Age 40 Years Undergoing RIC or NMA Allogeneic
Characteristic Age 40-54
Number of patients 614
Number of centers 120
Age, yr, median (range) 49 (40-54)
Male sex, n (%) 406 (66)
KPS 80% before HCT, n (%) 512 (83)
Missing KPS, n (%) 38 (6)
Previous autologous HCT, n (%) 160 (26)
NHL histology, n (%)*
Aggressive 299 (49)
Indolent 315 (51)
Disease status at HCT, n (%)
CR1/CR2þ 173 (28)
PR1/PR2þ 233 (38)
RD 155 (25)
Unknown or untested sensitivity 53 (9)
Interval from diagnosis to HCT, n (%)
<2 yr 217 (35)
2 yr 397 (65)
Donorerecipient sex match, n (%)
Maleemale 262 (43)
Maleefemale 122 (20)
Femaleemale 144 (23)
Femaleefemale 86 (14)
Donor/recipient CMV serostatus, n (%)
/ 193 (31)
/þ 171 (28)
þ/þ 173 (28)
þ/ 60 (10)
Unknown 17 (3)
Graft source, n (%)
Bone marrow 84 (14)
PBSCs 530 (86)
HLA match, n (%)
HLA-identical sibling 262 (43)
URD, well matched 222 (36)
URD, partially matched 95 (15)
URD, mismatched 15 (2)
URD, missing 20 (3)
Year of HCT, n (%)
2001-2004 363 (59)
2005-2007 251 (41)
Conditioning regimen intensity, n (%)
RIC 333 (54)
NMA 281 (46)
Conditioning regimen
TBI 200 cGy 111 (18)
TBI >200 cGy 21 (3)
Alkylator only (Cy, Mel, Bu, Thio); no TBI 443 (72)
Other 39 (6)
GVHD prophylaxis
CSA  MTX  other 205 (33)
Tac  MTX  other 179 (29)
T cell depletiony 230 (37)
Follow-up of survivors, mo, median (range) 56 (3-111)
RIC indicates reduced-intensity conditioning; NMA, nonmyeloablative; HCT, hemat
Performance Status; CR1/CR2+, complete remission; PR1/PR2+, partial remission;
cells; HLA, human leukocyte antigen; URD, unrelated donor; TBI, total body irradi
GVHD, graft-versus-host disease; CSA, cyclosporine; MTX, methotrexate; Tac, tacr
* Detailed in Methods, Patient Selection.
y Includes in vivo (antithymocyte globulin or alemtuzumab) and ex vivo T cell dRD), and interval from diagnosis to perfomance of HCT (<2 years versus 2
years). The International Prognostic Index (IPI) was considered, but lactate
dehydrogenase was not reported for 69% of the patients, and thus it could
not be assigned. The presence of extranodal sites and the number of pre-
transplantation therapies were considered as well.
Transplantation-related variables included era of transplantation (2001
to 2004 versus 2005 to 2007), donor/recipient cytomegalovirus (CMV)
serostatus (/ versus /þ versus þ/ versus þ/þ), HLA matching (HLA-
matched sibling donor versus well-matched URD versus partially matched
URD versus mismatched URD), stem cell source (bone marrow versus pe-
ripheral blood stem cells [PBSCs]), GVHD prophylaxis (cyclosporine [CSA] 
methotrexate [MTX]  other versus tacrolimus [Tac]  MTX  other versus
Tcell depletion), donorerecipient sexmatch (maleemale versusmaleefemaleHCT for NHL
Age 55-64 Age 65 P Value
552 82
112 45
59 (55-64) 67 (65-75) <.0001
359 (65) 64 (78) .06
481 (87) 71 (87) .24
30 (5) 2 (2)
131 (24) 7 (9) .002
.0008
314 (57) 55 (67)
238 (43) 27 (33)
.79
160 (29) 19 (23)
218 (39) 32 (39)
126 (23) 25 (30)
48 (9) 6 (7)
.12
167 (30) 31 (38)
385 (70) 51 (62)
.04
230 (42) 51 (62)
109 (20) 9 (11)
129 (23) 13 (16)
84 (15) 9 (11)
.41
142 (26) 19 (23)
171 (31) 24 (29)
170 (31) 31 (38)
55 (10) 6 (7)
14 (3) 2 (2)
.53
78 (14) 15 (18)
474 (86) 67 (82)
.29
208 (38) 29 (35)
234 (42) 39 (48)
76 (14) 9 (11)
17 (3) 1 (1)
17 (3) 4 (5)
<.0001
243 (44) 36 (44)
309 (56) 46 (56)
.05
260 (47) 43 (52)
292 (53) 39 (48)
.25
129 (23) 17 (21)
22 (4) 4 (5)
359 (65) 57 (70)
42 (8) 4 (5)
.43
162 (29) 19 (23)
172 (31) 25 (30)
218 (39) 38 (46)
47 (2-111) 47 (2-86)
opoietic cell transplantation; NHL, Non-Hodgkin lymphoma; KPS, Karnofsky
RD, resistant disease; CMV, cytomegalovirus; PBSCs, peripheral blood stem
ation; Cy, cyclophosphamide; Mel, melphalan; Bu, busulfan; Thio, thiotepa;
olimus.
epletion.
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tensity (RIC versusNMA). All risk factorswith a P value<.05were included in
the models. The potential interaction between the main effect of age and all
signiﬁcant covariates were examined. To analyze any possible impact of
speciﬁc histology on outcomes, we divided patients into 5 histological
groups (diffuse large B cell, mantle cell, SLL/CLL, follicular, and other) and
included these in the models for relapse/progression, PFS, and OS. All com-
putations were performed using SAS version 9.1 (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Table 1 summarizes patient-, disease-, and transplantation-
related variables for the 3 age cohorts. The 1248 patients in
the study population included 614 (49%) age 40 to 54 years,
552 (44%) age 55 to 64 years, and 82 (7%) age 65 years. The
majority of patients underwent transplantation for aggres-
sive NHL subtypes, which were most frequent in the oldest
patient group (49% for 40 to 54 years versus 57% for 55 to 64
years versus 67% for 65 years; P ¼ .0008). The oldest group
also had the lowest rate of previous autologous HCT (26% for
40 to 54 years versus 24% for 55 to 64 years versus 9% for65
years; P ¼ .002). A total of 225 patients with aggressive NHL
and 73 patients with indolent NHL had undergone previous
autologous HCT. Across the age cohorts, 23% to 30% of
all patients underwent transplantation with RD, including
30% of the oldest group. Use of an HLA-matched related
sibling donor or URD was similar across the age cohorts. The
remaining variablesdsex, KPS, interval from diagnosis to
transplantation, donorerecipient sex match, donor and re-
cipient CMV serostatus, and donorerecipient HLA matchd
were balanced across age cohorts. GVHD prophylaxis most
often included a calcineurin inhibitor with or without meth-
otrexate, but 37% to 46% of patients underwent T cell deple-
tion, with the highest rate in the oldest age cohort. Median
follow-up for the 3 age cohorts ranged from 47 to 56 months.Neutrophil Recovery and GVHD
Neutrophil recovery by dayþ28 post-transplantationwas
similar across the 3 age cohorts (Table 2). Multivariate anal-
ysis demonstrated that older age (odds ratio [OR], 0.32; 95%
CI, 0.14 to 0.75; P¼ .0085), KPS<80% (OR, 0.28; 95% CI, 0.21 to
1.85; P ¼ .0002), and RD status at HCT (OR, 0.25; 95% CI, 0.10
to 0.60; P ¼ .002) were associated with a lower likelihood
of prompt engraftment. The use of PBSC grafts versus boneTable 2
Univariate Analysis of Outcomes for All Patients Age  40 Years Undergoing RIC or
Outcome event Age 40-54 Age 55-64
n Probability (95% CI), % n P
Neutrophil engraftment 614 552
28 d 96 (95-97) 9
Acute GVHD grade II-IV 614 552
100 d 35 (31-39) 3
Chronic GVHD 612 551
3 yr 56 (52-60) 5
NRM 605 552
100 d 13 (10-16) 1
1 yr 22 (19-26) 2
Progression/relapse 605 552
3 yr 28 (24-32) 3
PFS 605 552
3 yr 44 (39-48) 3
OS 614 552
3 yr 54 (50-58) 4
RIC indicates reduced-intensity conditioning; NMA, nonmyeloablative; HCT, hemat
graft-versus-host disease; NRM, nonrelapse mortality; PFS, progression-free surviv
* Pointwise P value.marrowgrafts was associatedwith faster neutrophil recovery
(OR, 3.09; 95% CI, 1.64 to 5.85; P ¼ .0005).
The incidence of grade II-IV acute GVHD (33% to 35% by
day þ100; P ¼ .92) and chronic GVHD (48 to 56% by 3 years;
P ¼ .39) was similar across the 3 age cohorts (Table 2).
Multivariate analysis demonstrated no impact of age on
acute or chronic GVHD, but did show a higher risk of acute
GVHD in patients not in CR at time of HCT (PR1/PR2: risk
ratio [RR], 1.37; 95% CI, 1.08 to 1.75; P ¼ .01; RD: RR, 1.46; 95%
CI, 1.12 to 1.91; P ¼ .0005) and with the use of RIC versus an
NMA conditioning regimen (RR, 1.31; 95% CI, 1.08 to 1.59; P ¼
.007). The use of a non-CSA-containing GVHD prophylaxis
regimen was associated with less acute GVHD (Tac MTX 
other: RR, 0.76; 95% CI, 0.60 to 0.96; P ¼ .02; T cell depletion:
RR, 0.45; 95% CI, 0.35 to 0.57; P < .001). Compared with HLA-
matched sibling HCT, URD HLA-mismatched (URD well-
matched: RR, 1.45; 95% CI, 1.20 to 1.75; P ¼ .002; URD
partially HLA-matched: RR, 1.75; 95% CI, 1.35 to 2.26; P <
.001), and RIC conditioning regimen (RR, 1.29; 95% CI, 1.32 to
3.36; P < .002) were all associated with a higher incidence of
chronic GVHD.NRM
The cumulative incidence of NRM did not differ signiﬁ-
cantly among the 3 age cohorts at either day þ100 (13% to
18%; P ¼ .11) or 1 year (22% to 34%; P ¼ .05) post-
transplantation (Table 2). Univariate analyses stratiﬁed by
disease histology (aggressive versus indolent) also showed
no impact of age on NRM at these same time points (Table 3).
Because too few patients in the oldest cohort (n ¼ 7) had
undergone previous autologous HCT, we performed a sepa-
rate analysis in the 2 younger cohorts comparing outcomes
in those with and those without previous autologous HCT.
We found a higher 3-year NRM in patients who had received
an autograft before undergoing allogeneic HCT (previous
autograft: 42%; 95% CI, 25% to 31%; no previous autograft:
28%; 95% CI, 37% to 48%; P < .0001). In multivariate analysis,
older age was associated with worse NRM (age 55 to 64
years: RR, 1.52; 95% CI, 1.24 to 1.86; P < .001; age 65 years:
RR, 1.57; 95% CI, 1.08 to 2.29: P ¼ .02), although NRM was
similar in the 2 older age cohorts (Table 4). Lower KPS,
advanced disease at HCT, and less favorable HLA match also
adversely impacted NRM.NMA Allogeneic HCT for NHL
Age 65 P Value*
robability (95% CI), % n Probability (95% CI), %
82
6 (94-97) 89 (82-95) .09
82
4 (30-38) 33 (23-44) .92
82
4 (49-58) 48 (37-59) .39
82
7 (14-20) 18 (11-28) .11
7 (23-31) 34 (24-44) .05
82
3 (29-37) 33 (23-44) .22
82
2 (28-36) 27 (17-37) <.0001
82
0 (36-44) 39 (28-50) <.0001
opoietic cell transplantation; NHL, Non-Hodgkin lymphoma; GVHD indicates
al; OS, overall survival.
Table 3
Univariate Outcomes by Disease Histology for Patients Age 40 Years Undergoing RIC or NMA Allogeneic HCT for NHL
Outcome Event Age 40-54 Age 55-64 Age 65 P Value*
n Probability (95% CI), % n Probability (95% CI), % n Probability (95% CI), %
Aggressive NHL
NRM 297 314 55
100 d 13 (9-17) 16 (12-20) 24 (13-36) .15
1 yr 22 (17-27) 26 (22-32) 38 (26-51) .05
Progression/relapse 297 314 55
3 yr 34 (28-39) 36 (31-42) 29 (18-42) .55
PFS 297 314 55
3 yr 38 (32-44) 30 (25-35) 25 (14-37) .04
OS 299 314 55
3 yr 50 (44-56) 37 (31-43) 34 (21-47) .003
Indolent NHL
NRM 308 238 27
100 d 13 (9-17) 18 (13-23) 8 (1-20) .10
1 yr 23 (18-27) 27 (22-33) 24 (10-42) .46
Progression/relapse 308 238 27
3 yr 23 (18-27) 28 (22-34) 41 (23-61) .11
PFS 308 238 27
3 yr 49 (43-55) 35 (29-41) 30 (13-50) .003
OS 315 238 27
3 yr 58 (52-63) 44 (38-51) 50 (30-79) .013
RIC indicates reduced-intensity conditioning; NMA, nonmyeloablative; HCT, hematopoietic cell transplantation; NHL, Non-Hodgkin lymphoma; NRM, non-
relapse mortality; PFS, progression-free survival; OS, overall survival.
* Pointwise P value.
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Relapse and progression rates at 3 years post-
transplantation were similar across the 3 age cohorts, as
conﬁrmed in a separate analysis stratiﬁed by disease histol-
ogy (Tables 2 and 3; Figure 1A and C). In the youngest and
middle cohorts, relapse incidence was similar in patients
who underwent previous autologous HCT (30% at 3 years;
P ¼ .88). Multivariate analysis demonstrated no signiﬁcant
impact of age, but advanced disease at HCT and GVHD pro-
phylaxis were associated with increased risk of progression
or relapse. T cell depletionwas associated with a signiﬁcantly
increased risk of progression or relapse (RR, 1.52; 95% CI, 1.18
to 1.95; P ¼ .001). The number of extramedullary sites
involved and number of pretransplantation therapies did not
inﬂuence the risk of relapse (P > .10).
PFS and OS
In univariate analysis, PFS at 3 years was highest in the
youngest age cohort, and there was no difference in PFS
between the 2 older cohorts (Table 2 and Figure 2A). PFS also
differed among the age cohorts when patients were stratiﬁed
by aggressive/indolent disease histology (Table 3; Figures 1B
and D and 2A). Multivariate analysis showed that older age
(55 and >65 years), lower KPS (<80%), disease status other
than CR1/CR2, GVHD prophylaxis, and greater HLAmismatch
were all associated with inferior PFS (Table 4).
Three-year OS also differed signiﬁcantly across the 3 age
cohorts (Table 2 and Figure 2B), although even in the oldest
cohort, 39% of patients survived beyond 3 years. In the
youngest and middle cohorts, previous autologous HCT was
associated with lower 3-year OS (previous autograft: 35%;
95% CI, 30% to 41%; no previous autograft: 52%; 95% CI, 48% to
55%; P < .0001). In multivariate analysis, older age was
associated with worse OS, as were disease status at alloge-
neic HCT, KPS <80%, HLA mismatch, and use of an RIC
regimen (Table 4). After HCT, the primary causes of death
were similar in the 3 age cohorts: relapse (33% to 37%),
infection (17% to 21%), GVHD (14% to 17%), and organ failure
(13% to 15%).To examine the effect of histology on outcomes, we
assessed the impact of 5 speciﬁc histological subgroups on
the incidence of relapse/progression, PFS, and OS. Multivar-
iate analysis revealed no signiﬁcant inﬂuence of these his-
tological subgroups on any outcome (P > .10 for all). In
addition, NHL subtype (B cell or a T cell subtype) had no
signiﬁcant effect on any outcome (P > .30 for all). Neither the
number of extramedullary sites involved nor the number of
pretransplantation therapies inﬂuenced PFS or OS (P > .10
for both).
DISCUSSION
We examined the impact of age in a large group of older
patients undergoing RIC or NMA allogeneic HCT for NHL. In
this sizeable cohort, we found that only a modest number of
patients over age 65 years underwent allogeneic HCT to treat
their disease. Although age had a modest adverse effect in
patients over age 55 compared with those age 40 to 54,
outcomes were equivalent in patients age 55 to 64 and those
age65, with no signiﬁcant differences in NRM, relapse, PFS,
or OS. Older age also did not inﬂuence the incidence of acute
or chronic GHVD, major complications that might be less
well tolerated by older patients.
It is not surprising that HLA disparity, poorer KPS, T cell
depletion, and advanced disease status at time of trans-
plantation adversely affected major HCT outcomes, given
that each has been reported to have prognostic implications
[9,16-20]. Aggressive NHL is also generally associated with
worse outcomes [21,22]. Although histological subgroup had
no signiﬁcant association with any HCT outcome in multi-
variate analysis, 67% of all patients age 65 years and 57% of
those age 55 to 64 years had aggressive NHL. The small
number of patients in the oldest age cohorts might have
limited these analyses. Few patients in the oldest cohort had
undergone previous autologous HCT, which precluded the
inclusion of this cohort in the analysis for the effect of pre-
vious autologous HCT. In the 2 younger cohorts, however, we
found an adverse effect of previous autologous HCT on both
NRM and OS. Two previous small series also reported a
Table 4
Multivariate Analysis of NRM, Relapse/Progression, PFS, and OS after RIC or NMA Allogeneic HCT for NHL
Variable n Relative Risk (95% CI) P Value* Overall P Value
NRM
Age, yr
40-54 614 .0002
55-64 552 1.52 (1.24-1.86) <.0001
65 82 1.57 (1.08-2.29) .0189
Signiﬁcant covariates
KPS
80 1064 .0001
<80 114 1.87 (1.40-2.50) <.0001
NHL disease status
CR1/CR2þ 352 <.0001
PR1/PR2þ 483 1.27 (0.99-1.63) .0576
RD 306 1.90 (1.45-2.49) <.0001
HLA match
HLA-identical sibling 499 <.0001
URD well matched 495 1.36 (1.07-1.71) .0116
URD partially matched 180 2.30 (1.74-3.03) <.0001
URD mismatched 33 2.9 (1.76-4.77) <.0001
Relapse
Age, yr
40-54 614 .059
55-64 552 1.29 (1.05-1.59) .0176
65 82 1.18 (0.78-1.77) .4321
Signiﬁcant covariates
NHL disease status
CR1/CR2þ 352 <.0001
PR1/PR2þ 483 1.67 (1.27-2.19) .0002
RD 306 2.73 (2.04-3.64) <.0001
GVHD prophylaxis
CSA  MTX  other 386 <.0001
Tac  MTX  other 376 0.88 (0.67-1.16) .3607
T cell depletion 486 1.52 (1.18-1.95) .0011
PFS
Age, yr
40-54 614 .0001
55-64 552 1.37 (1.18-1.59) <.0001
65 82 1.34 (1.01-1.76) .0397
Signiﬁcant covariates
KPS
80 1064 <.0001
<80 114 1.63 (1.30-2.05) <.0001
NHL disease status
CR1/CR2þ 352 <.0001
PR1/PR2þ 483 1.45 (1.21-1.75) <.0001
RD 306 1.45 (1.88-2.78) <.0001
GVHD prophylaxis
CSA  MTX  other 386 .0001
Tac  MTX  other 376 0.87 (0.72-1.06) .1655
T cell depletion 486 1.26 (1.05-1.50) .0129
HLA match
HLA-identical sibling 499 <.0001
URD well matched 495 1.13 (0.96-1.34) .1468
URD partially matched 180 1.39 (1.12-1.72) .0029
URD mismatched 33 2.28 (1.56-3.32) <.0001
OS
Age, yr
40-54 614 <.0001
55-64 552 1.47 (1.25-1.72) <.0001
65 82 1.47 (1.09-1.98) .0127
Signiﬁcant covariates
NHL disease status
CR1/CR2þ 352 <.0001
PR1/PR2þ 483 1.29 (1.06-1.58) .0113
RD 306 1.97 (1.60-2.44) <.0001
KPS
80 1064 <.0001
<80 114 1.87 (1.48-2.37) <.0001
HLA match
HLA-identical sibling 499 <.0001
URD well matched 495 1.30 (1.09-1.56) .0043
URD partially matched 180 1.90 (1.52-2.38) <.0001
URD mismatched 33 2.21 (1.48-3.30) .0001
Conditioning regimen .03
NMA 612
RIC 636 1.19 (1.02-1.39) .03
NRM indicates nonrelapse mortality; PFS, progression-free survival; OS, overall survival; RIC, reduced-intensity conditioning; NMA, nonmyeloablative; HCT, he-
matopoietic cell transplantation; NHL, Non-Hodgkin lymphoma; KPS, Karnofsky Performance Status; CR1/CR2þ, complete remission; PR1/PR2þ, partial remission;
RD, resistant disease;HLA,human leukocyte antigen;URD,unrelateddonor;GVHD, graft-versus-host disease;CSA, cyclosporine ;MTX,methotrexate; Tac, tacrolimus.
* Compared with reference group.
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Figure 1. Three-year relapse and PFS based on histology. (A) Progression/relapse, aggressive NHL. (B) PFS, aggressive NHL. (C) Progression/relapse, indolent NHL. (D)
PFS, indolent NHL.
B.L. McClune et al. / Biol Blood Marrow Transplant 20 (2014) 960e968966modest negative inﬂuence of previous autologous HCT on
subsequent allogeneic HCT. Thomson et al. [23] found no
inﬂuence of previous autologous HCT on outcomes, whereas
Rodriguez et al. [24] reported an association between pre-
vious autologous HCT and worse relapse and OS, and a trend
toward an association with worse NRM. Given that autolo-
gous HCT remains the initial HCT option for most patients
with NHL, the impact of previous autografting directly in-
ﬂuences the selection of patients for allografting.
Even for patients with advanced NHL, the outcomes of RIC
or NMA allogeneic HCT seen in the present study are
encouraging. This is important, considering that patients
who relapse after autologous HCT have very poor median
survival, ranging from 3 to 8 months depending on NHL
histological type [25-27]. One study found a median survival
of just 23 months in patients with mantle cell lymphoma
who relapsed after autologous HCT, and only 6 months if
relapse occurred within 1 year after HCT [28]. In another
study of patients with relapsed/refractory diffuse large B cell
lymphoma, 36% of patients who received second-line salvageFigure 2. Three-year PFS (A) and OS (therapy failed to respond, and in those who did respond, the
median duration of responsewas only 4months [29]. A study
of survival after relapse post-autografting using an age-
adjusted IPI found a PFS of only 16% and an OS of only 18%
at 4 years, even in patients with chemosensitive disease [27].
In the present study, 3-year OS was 39% in the oldest age
cohort, suggesting that selected older patients can beneﬁt
from allogeneic HCT and can achieve extended survival that
cannot be attained with other salvage approaches.
We were surprised at how few patients age 65 years
underwent allogeneicHCT, even thoughmore thanone-half of
all NHL cases occur in patients age 60 years [30]. Similar to
observations in patients with acute myelogenous leukemia
and myelodysplastic syndrome, the majority of patients with
NHL eligible for allogeneic HCT are not referred and never
receive this therapy [31]. Contemporary registryanalyses from
the European Group for Blood and Marrow Transplantation
and the CIBMTR examining relapsed high-grade lymphomas
have emphasized the curative potential of this therapy
[32,33], yet recognize the rarity of its use. Thus, HCT remainsB) after allogeneic HCT for NHL.
B.L. McClune et al. / Biol Blood Marrow Transplant 20 (2014) 960e968 967not widely applied despite recent reports of improved HCT
outcomes for patients in the modern era [34-37].
We note some limitations of our study owing to the het-
erogeneity of pre-HCT therapies and lack of direct data to
clarify the medical decision making when selecting patients
for allogeneic HCT. Detailed comorbidity information other
than KPS was not available for this study, although this in-
formationmay directly inform patient selection by physicians
considering allogeneic HCT. Although some appropriate clin-
ical selection bias exists in choosing only the ﬁttest older pa-
tients for an allograft, these promising outcomes suggest that
careful pretransplantation evaluation can identify patients
able to tolerate this curative therapeutic approach.
Although our results suggest that outcome differences are
only modestly inﬂuenced by age, even our oldest patients
had encouraging outcomes. Attention to disease stage, HLA
disparity, and performance status before HCT could further
improve these results by identifying those patients with NHL
most likely to beneﬁt from RIC allogeneic HCT. Our analysis
supports the referral of selected older patients with NHL for
allogeneic HCT.
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